| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| GDNF | HOT GMP-GDFH17 | GMP Human GDNF Protein (E. coli) | Human | E. coli | ![]() | MSSDS-PAGE | $700.00 50ug | ||
| GDNF | Human GDNF / ATF / hGDNF Protein (E. coli), premium grade | Human | E. coli | ![]() | SDS-PAGE | $270.00 20ug | |||
| GDNF | Human GDNF / ATF / hGDNF Protein (E. coli), Research Grade | Human | E. coli | ![]() | SDS-PAGE | $200.00 20ug | |||
| GDNF | Human GDNF / ATF / hGDNF Protein, premium grade | Human | HEK293 | ![]() | SDS-PAGE | $245.00 20ug | |||
| GDNF | Mouse GDNF / ATF Protein, His Tag, low endotoxin (MALS verified) | Mouse | HEK293 | ![]() | MALSSDS-PAGE | $205.00 20ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| AB-1005 | AMT-140; AB-1005; AAV2-GDNF; AAV2-GDNF-MSA; AAV2-GDNF-PD | Phase 2 Clinical | Uc San Francisco | Multiple System Atrophy; Parkinson Disease | Details |
| NRO-1 | NRO-1; SI-01 | Phase 2 Clinical | Senju Pharmaceutical Co Ltd | Xerophthalmia | Details |
| Ifezuntirgene inilparvovec | AAV5-miSNP15; AMT-130; AAV5-miHtt12; AAV5-miSNP7 | Phase 2 Clinical | Amsterdam Molecular Therapeutics, Uniqure | Huntington Disease | Details |
| AAV2-GDNF gene therapy (NINDS) | Phase 1 Clinical | National Institute Of Neurological Disorders And Stroke | Parkinson Disease | Details | |
| RGL-193 | RGL-193 | Phase 1 Clinical | Shanghai Regenelead Therapies Co Ltd | Parkinson Disease | Details |
